Detalles de la búsqueda
1.
Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology.
Value Health
; 2022 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977878
2.
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
BMC Cardiovasc Disord
; 17(1): 224, 2017 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28814290
3.
Acute and chronic impact of cardiovascular events on health state utilities.
BMC Health Serv Res
; 15: 173, 2015 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-25896804
4.
Cost effectiveness of long-acting risperidone in Sweden.
Appl Health Econ Health Policy
; 8(5): 327-41, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20804225
5.
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
BMC Neurol
; 9: 6, 2009 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19208243
6.
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Clin Ther
; 30(9): 1704-13, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18840377
7.
A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
Appl Health Econ Health Policy
; 6(4): 189-97, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19382819
8.
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
J Med Econ
; 20(8): 799-812, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28485692
9.
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Clin Ther
; 39(4): 771-786.e3, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28366593
10.
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Clin Cardiol
; 39(6): 313-20, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27092712
11.
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain.
Clinicoecon Outcomes Res
; 7: 105-17, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25709480
12.
Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
Pharmacoeconomics
; 21(1): 39-48, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12484802
13.
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.
Eur J Hosp Pharm
; 20(4): 227-231, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23888248
14.
Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection.
Schizophr Res Treatment
; 2012: 791468, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22966445
15.
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
J Opioid Manag
; 7(4): 287-96, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21957828
16.
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
Pharmacoeconomics
; 28 Suppl 1: 49-57, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21182343
17.
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
Eur J Health Econ
; 11(6): 585-94, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20084535
18.
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Pharmacoeconomics
; 28 Suppl 1: 107-28, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21182347
19.
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Pharmacoeconomics
; 28 Suppl 1: 169-81, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21182350
20.
Economic evidence in affective disorders: a review.
Eur J Health Econ
; 5 Suppl 1: S12-20, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15754066